Effect of curcumin on the proliferation, apoptosis, migration, and invasion of human melanoma A375 cells

Genetics and Molecular Research

Volumn 14, Issue 1, 2015, Pages 1056-1067

  Zhang, Y P ^a   Li, Y Q ^a   Lv, Y T ^a   Wang, J M ^a  

^a LIAOCHENG PEOPLE'S HOSPITAL   (China)

Author keywords

Apoptosis; Curcumin; Invasion; Melanoma; Migration; Proliferation

Indexed keywords

CURCUMIN; GELATINASE A; GELATINASE B; JANUS KINASE 2; PROTEIN BCL 2; STAT3 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; JAK2 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN;

A375 CELL LINE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL INVASION; CELL MIGRATION; CELL STRUCTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; MELANOMA; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR INVASION;

CURCUMA LONGA;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CURCUMIN; HUMANS; JANUS KINASE 2; MELANOMA; NEOPLASM INVASIVENESS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84922438955     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2015.February.6.9     Document Type: Article

References (20)

1. Avril MF, Aamdal S, Grob JJ, Hauschild A, et al. (2004). Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J. Clin. Oncol. 22: 1118-1125.
2. Bedikian AY, Millward M, Pehamberger H, Conry R, et al. (2006). Bcl-2 antisense (oblimersensodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J. Clin. Oncol. 24: 4738-4745.
3. Chatterjee SJ and Pandey S (2011). Chemo-resistant melanoma sensitized by tamoxifen to low dose curcumin treatment through induction of apoptosis and autophagy. Cancer Biol. Ther. 11: 216-228.
4. Cummins DL, Cummins JM, Pantle H, Silverman MA, et al. (2006). Cutaneous malignant melanoma. Mayo Clin. Proc. 81: 500-507.
5. Hamsa TP and Kuttan G (2010). Harmine inhibits tumour specific neo-vessel formation by regulating VEGF, MMP, TIMP and pro-inflammatory mediators both in vivo and in vitro. Eur. J. Pharmacol. 649: 64-73.
6. Haura EB, Turkson J and Jove R (2005). Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer. Nat. Clin. Pract. Oncol. 2: 315-324.
7. Kortylewski M and Yu H (2008). Role of Stat3 in suppressing anti-tumor immunity. Curr. Opin. Immunol. 20: 228-233.
8. Lacreusette A, Barbieux I, Nguyen JM, Pandolfino MC, et al. (2009). Defective activations of STAT3 Ser727 and PKC isoforms lead to oncostatin M resistance in metastatic melanoma cells. J. Pathol. 217: 665-676.
9. Menon LG, Kuttan R and Kuttan G (1995). Inhibition of lung metastasis in mice induced by B16F10 melanoma cells by polyphenolic compounds. Cancer Lett. 95: 221-225.
10. Menon LG, Kuttan R and Kuttan G (1999). Anti-metastatic activity of curcumin and catechin. Cancer Lett. 141: 159-165.
11. Messina JL, Yu H, Riker AI, Munster PN, et al. (2008). Activated stat-3 in melanoma. Cancer Control 15: 196-201.
12. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, et al. (2000). Randomized phase III study oftemozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol. 18: 158-166.
13. Odot J, Albert P, Carlier A, Tarpin M, et al. (2004). In vitro and in vivo anti-tumoral effect of curcumin against melanoma cells. Int. J. Cancer 111: 381-387.
14. Okada A (1999). Roles of matrix metalloproteinases and tissue inhibitor of metalloproteinase (TIMP) in cancer invasion and metastasis. Gan To Kagaku Ryoho 26: 2247-2254.
15. Ravdel L, Robinson WA, Lewis K and Gonzalez R (2006). Metastatic melanoma in the breast: a report of 27 cases. J. Surg. Oncol. 94: 101-104.
16. Schindler C, Levy DE and Decker T (2007). JAK-STAT signaling: from interferons to cytokines. J. Biol. Chem. 282: 20059-20063.
17. Wang ZD, Huang C, Li ZF, Yang J, et al. (2010). Chrysanthemum indicum ethanolic extract inhibits invasion of hepatocellular carcinoma via regulation of MMP/TIMP balance as therapeutic target. Oncol. Rep. 23: 413-421.
18. Xie TX, Wei D, Liu M, Gao AC, et al. (2004). Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 23: 3550-3560.
19. Yagil Z, Kay G, Nechushtan H and Razin E (2009). A specific epitope of protein inhibitor of activated STAT3 is responsible for the induction of apoptosis in rat transformed mast cells. J. Immunol. 182: 2168-2175.
20. Zhuang L, Lee CS, Scolyer RA, McCarthy SW, et al. (2007). Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Mod. Pathol. 20: 416-426.